Last updated: May 25, 2026
Ziprasidone mesylate is a small-molecule antipsychotic supplied through a multi-tier procurement chain spanning API manufacturers, intermediate producers, and finished-dose makers. In US commercial supply, the key sourcing risk is not patentability for supply continuity but regulatory standing (DMF/CEP support), CMC transferability, and ANDA compatibility with the Orange Book reference listed drug (RLD). A buyer should validate (1) whether the supplier is producing ziprasidone mesylate drug substance versus a salt conversion from ziprasidone base, (2) DMF or CEP status and cross-referenced data integrity, (3) polymorph and solvates controls for the salt form, (4) particle size and dissolution specs consistent with the ANDA comparability dossier, and (5) global regulatory history and inspection outcomes.
The list below is structured to support procurement and vendor due diligence for ziprasidone mesylate across API, solid-state salt handling, and finished-dose manufacturing.
Which companies supply ziprasidone mesylate API and drug substance?
Featured snippet answer: Ziprasidone mesylate API supply is concentrated among global generic API and specialty intermediate plants that file Drug Master Files (DMFs) for the US and/or hold equivalent EU documentation (eg, CEPs). Finished-dose supply is then handled by ANDA manufacturers and labelers that source drug substance and execute formulation, blending, granulation, tablet/capsule finishing, and packaging under cGMP.
API supply due diligence checklist (what procurement teams must confirm)
- Salt form control: confirm validated process controls for ziprasidone mesylate crystallization, residual solvents, water content, and polymorph/solid-state specs.
- Manufacturing route: verify whether the supplier makes the mesylate directly or via conversion from ziprasidone base; request process description and critical parameters.
- Regulatory support: confirm whether the supplier has an active US DMF cross-reference capability for the ANDA manufacturer’s filing or an equivalent dossier for other markets.
- Analytical package: require method ownership or transfer rights for assay, impurities, residual solvents, salt-specific identity tests, and dissolution method comparability.
- Quality history: ask for FDA/EMA inspection outcomes tied to the last inspection cycle and CAPA themes.
API and intermediate suppliers: typical profiles seen in commercial supply
Because ziprasidone mesylate is generic, API procurement commonly includes:
- US DMF-holding API manufacturers supplying multiple ANDA filers.
- Integrated intermediate-to-API specialty chemical firms supplying key chiral/bicyclic intermediates that feed API synthesis.
- Salt-manufacturing and crystallization specialists when mesylate control is a critical differentiator for dissolution.
(For a procurement decision, vendor qualification is driven by dossier support, not marketing claims.)
Who manufactures ziprasidone mesylate finished dosage forms (tablets/capsules) and who are the major labelers?
Featured snippet answer: The finished-dose market for ziprasidone mesylate is supplied by generic manufacturers who run tablet/capsule formulation and packaging using internally made or externally sourced ziprasidone mesylate drug substance. Brand supply is handled by the original NDA holder and/or authorized manufacturers, with generic supply driven by ANDA labelers.
Finished dosage forms commonly in circulation
- Ziprasidone mesylate tablets (immediate-release)
- Zeldox-equivalent strengths (US market commonly tracks zeldox strengths and the generic label strengths; ensure strength-by-strength matching for formulation equivalence and dissolution).
Procurement validation for finished-dose suppliers
- Strength and release form: ensure exact strength (mg) matching for purchasing and patient dosing.
- Bioequivalence basis: confirm whether the finished product is tied to an ANDA with BE demonstration and whether formulation changes were approved.
- Packaging and stability: verify shelf life, storage conditions, and stability protocol alignment with the supplier’s current packaging configuration.
- Supply chain controls: confirm ingredient tracing for API batches, including intermediate and salt conversion steps.
What patents protect ziprasidone mesylate supply (API, salts, formulations, and methods of use)?
Featured snippet answer: For ziprasidone mesylate, most enforceable IP is long expired or limited to later-developed formulation, method-of-use, or specific manufacturing improvements. For supply decisions, the highest practical IP friction usually arises from (1) formulation-specific dissolution or polymorph control patents and (2) method-of-use patents tied to specific indications or dosing regimens, not from the base drug substance identity.
Patent estate relevance for supplier selection
Procurement and sourcing teams should align supplier risk screening with:
- Salt-form and solid-state control patents (if any still active)
- Formulation patents for specific excipient systems that affect dissolution and BE
- Process patents for API or salt crystallization steps
Practical litigation/IP risk screening (what to check in diligence)
- Whether supplier’s ANDA references a particular RLD and whether it uses a formulation cleared under the same IP landscape.
- Whether any supplier-owned process steps are covered by active method/process patents.
When does ziprasidone mesylate lose exclusivity, and what does that mean for supplier competition?
Featured snippet answer: Ziprasidone mesylate is a long-established drug; exclusivity and brand-level barriers have largely elapsed. Competitive supply is therefore governed by regulatory and CMC execution rather than exclusivity expiration.
How exclusivity status affects sourcing
- Low exclusivity ceiling means multiple ANDA manufacturers can supply, but:
- Ongoing CMC comparability (dissolution, solid-state control, impurities profile) sets practical entry barriers.
- Inspection and batch release reliability sets ongoing supply stability.
What is the Orange Book status of ziprasidone mesylate products and what does it imply for sourcing?
Featured snippet answer: The Orange Book status for ziprasidone mesylate products dictates listing of patents and exclusivity for the RLD, and it informs which generic manufacturers can enter via ANDA and under what patent certifications (Paragraph IV, III, or I). For sourcing, the key implication is which ANDA products are currently eligible and stable in the market.
Sourcing implication by certification type
- Paragraph III products typically rely on patent expiration timing and listed patent status.
- Paragraph IV products introduce additional litigation risk for labelers and may affect supply continuity if settlements delay certain strengths.
What generic entry risks exist for ziprasidone mesylate tablets and how do they affect API sourcing?
Featured snippet answer: The principal entry risks are regulatory (ANDA approvability), CMC comparability (solid-state and dissolution), and litigation-driven supply disruptions. API sourcing risk spikes if only one or two DMF-supported suppliers can meet the ANDA’s validated impurity and dissolution target.
Where supply disruption typically originates
- API quality drift: changes in crystallization conditions and salt conversion.
- Inspection-driven downtime: repeated deviations that pause release.
- Regulatory dossier gaps: DMF cross-reference mismatch or unsupported changes.
How does ziprasidone mesylate compare with other ziprasidone formulations for supplier requirements?
Featured snippet answer: Ziprasidone is supplied commonly as the mesylate salt, and supplier qualification is sensitive to the salt form. Any comparison with free base or different salt forms matters only insofar as it changes solid-state specs, dissolution, and regulatory comparability.
Supplier requirements by formulation type
- Salt form production requires validated crystallization control.
- Dissolution performance drives selection of salt particle size, polymorph, and excipient blend.
Which manufacturing/IP barriers make ziprasidone mesylate hard to source reliably?
Featured snippet answer: The barriers are less about IP and more about solid-state reproducibility and dossier-supported manufacturing. Reliability comes from validated processes that produce consistent mesylate salt quality and impurity profiles.
Typical bottlenecks
- Mesylate crystallization reproducibility across campaigns
- Residual solvents and water content controls
- Impurities control tied to specific synthesis routes
- Transferability of analytical methods and batch records
What do bidders and investors track in the ziprasidone mesylate supply chain?
Featured snippet answer: Buyers and capital allocators track supplier regulatory standing, DMF status, batch release track record, and capacity stability in crisis periods.
Metrics to request in procurement or DDQs
- Batch rejection rate and OOS/OOT frequency for last 12-24 months
- DMF status (active, updated, cross-referenced)
- Inspection outcomes for last two cycles
- Capacity utilization and change control history for the salt crystallization step
Key Takeaways
- Ziprasidone mesylate supply is driven by DMF-supported API manufacturing, solid-state mesylate control, and cGMP reliability more than by exclusivity barriers.
- Supplier qualification should focus on salt form reproducibility, impurity and residual solvent control, and ANDAs’ dissolution comparability requirements.
- Procurement risk is concentrated in process stability and regulatory dossier integrity, which can create batch release interruptions even when raw material capacity exists.
FAQs
1) What documentation should I request from ziprasidone mesylate API suppliers for ANDA compatibility?
DMF cross-reference status, validated impurity and residual solvent specs, mesylate identity tests, dissolution relevance data, and the analytical method package with transfer rights.
2) Does ziprasidone mesylate supply depend on making the mesylate salt versus converting from ziprasidone base?
Yes. Procurement should validate the salt conversion route, because crystallization and residual impurities can change dissolution and comparability.
3) What quality attributes most often cause OOS/OOT issues for ziprasidone mesylate?
Salt solid-state attributes (polymorph/particle size), residual solvents/water content, and impurity profile drift across manufacturing campaigns.
4) How do Paragraph IV challenges affect ziprasidone mesylate supplier availability?
They can delay certain strengths or cause supply interruptions if litigation settlements impose launch timing or if manufacturing changes are constrained.
5) Are there meaningful differences between suppliers’ tablet dissolution profiles for ziprasidone mesylate?
Yes. Even with BE-approved products, supplier-to-supplier differences in solid-state processing can affect dissolution and require strict control of crystallization and formulation parameters.
References
- FDA. Approved Drug Products with Therapeutapeutic Equivalence Evaluations (Orange Book). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
- FDA. Drug Master Files (DMFs): Information for Applicants. U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-master-files-dmfs
- FDA. Abbreviated New Drug Application (ANDA). U.S. Food and Drug Administration. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda
